THE SCIENCE
Ipamorelin Research: One Receptor, One GH Pulse, a Two-Hour Half-Life
The mechanism, the human and animal kinetics, and the studies that anchor each claim — organized so the pharmacokinetics lead.
Before the details
Ipamorelin does one main thing: it presses a single button — the ghrelin receptor on the pituitary gland — and the gland answers with a brief pulse of growth hormone [3]. The button is formally called GHS-R1a (the growth hormone secretagogue receptor type 1a), and it is the same one the natural hunger hormone, ghrelin, uses [3]. What makes ipamorelin notable is that it presses that button cleanly: lots of growth hormone, almost none of the stress hormones that older peptides also triggered [3]. In humans, the growth-hormone pulse peaks about 40 minutes after a dose and the drug itself is half-gone every two hours [1]. This page walks through that mechanism, the kinetics in animals and people, the one human trial that read out, and how ipamorelin compares to the GHRH-type peptides it gets paired with. Every number traces to a study on the references page.
Mechanism: a selective ghrelin-receptor agonist
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) derived from GHRP-1 by removing a central Ala-Trp dipeptide [3]. It activates GHS-R1a on pituitary somatotrophs, the GH-producing cells, triggering a calcium-driven release of growth hormone [3]. Its founding characterization established the trait that named it: potent GH release with no meaningful rise in ACTH or cortisol, even above 200-fold its GH ED50 (swine ED50 = 2.3 nmol/kg) [3]. Because it works through a receptor distinct from the GHRH receptor, its GH-releasing action is complementary to GHRH — the mechanistic basis for combining it with GHRH analogs [3]. Class-level work confirms that endogenous GHRH tone is actually required for full secretagogue activity: in rats, blocking GHRH with antiserum or a receptor antagonist sharply attenuated GHRP-induced GH release [9].
Pharmacokinetics: the numbers that lead this site
In healthy male volunteers given five 15-minute IV infusions from 4.21 to 140.45 nmol/kg, ipamorelin showed dose-proportional kinetics: terminal half-life ~2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg, and a single GH pulse peaking ~40 minutes post-dose [1]. This is one of the only human ipamorelin datasets and the backbone of the digest. In rats, plasma clearance is roughly five-fold lower than GHRP-6 [1]. Ipamorelin itself is not orally bioavailable; the oral story belongs to engineered analogs such as NN703, which showed a 4.1-hour half-life and 30% oral bioavailability in dogs and was derived directly from ipamorelin to fix that limitation [10]. A broader medicinal-chemistry program used ipamorelin's pharmacophore to generate analogs with 10–55% oral bioavailability in dogs while keeping in-vivo potency in swine [11].
What is ipamorelin peptide
Ipamorelin peptide is a wholly synthetic five-amino-acid chain (a pentapeptide), not a hormone the body makes [3]. Its non-natural residues — alpha-aminoisobutyric acid at position 1, plus D-2-naphthylalanine and D-phenylalanine — make it resistant to the enzymes that would otherwise break a peptide down quickly [3]. Functionally it is a ghrelin mimetic: it imitates ghrelin at GHS-R1a to release growth hormone, but selectively, sparing cortisol and prolactin [3]. It carries the development code NNC 26-0161 and was discovered at Novo Nordisk [3].
The human trial that read out
The defining human efficacy anchor is the Phase 2 RCT for postoperative ileus (NCT00672074): 114 bowel-resection patients given 0.03 mg/kg IV twice daily for up to 7 days [2]. It missed its primary endpoint — median time to first tolerated meal 25.3 h with ipamorelin versus 32.6 h with placebo, p=0.15 [2]. Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, i.e. no ipamorelin-specific safety signal in that short window, but no demonstrated efficacy either [2]. No Phase 3 trial followed, and there is no approved indication [2].
Animal efficacy and the freshest data
In adult female Sprague-Dawley rats, subcutaneous ipamorelin at 18, 90, and 450 microg/day for 15 days raised longitudinal bone-growth rate from 42 to 44, 50, and 52 microns/day respectively — with no change in total IGF-1, IGFBPs, or bone-turnover markers, pointing to a partly local, GH-pulse-driven skeletal effect [4]. The most recent in-vivo study, in ferrets (2024), found intraperitoneal ipamorelin (1–3 mg/kg) inhibited cisplatin-induced body-weight loss by ~24% during the delayed phase, with no anti-emetic effect — a peripheral, weight-protective action [5]. A 2026 critical review of peptide use in sport flags ipamorelin as a widely promoted body-composition peptide with serious safety concerns in uncontrolled use and an expanding anti-doping detection framework [12].
Ipamorelin cjc-1295
The ipamorelin cjc-1295 pairing combines a GHRP (ipamorelin, acting on GHS-R1a) with a GHRH analog (CJC-1295, acting on the GHRH receptor) to engage two complementary pathways at once [3]. Class-level human work shows why: chronic GHRP-2 or GHRH dosing (7–30 days) converted an additive GHRP + GHRH GH response into a synergistic one in younger and older adults [13]. Combination GHRP + GHRH also overcomes somatostatin braking — hexarelin plus GHRH-(1-29) stayed synergistic even during high-dose somatostatin infusion that largely blunted GHRH alone [14]. Note these data use GHRP-2 and hexarelin, not ipamorelin itself; they establish the class principle, not an ipamorelin-specific combination outcome [13][14].
What is cjc 1295 ipamorelin
CJC-1295 ipamorelin is shorthand for the two-peptide combination above: CJC-1295 is a long-acting GHRH analog that raises the baseline GH-releasing drive, while ipamorelin adds a sharp, selective GH pulse on top [3]. The rationale is mechanistic complementarity — GHRH-receptor activation (cAMP) plus GHS-R1a activation (calcium) producing more GH together than either alone [3]. Importantly, the combination as a protocol has not been tested in a controlled human trial for any outcome; its support is the separate single-agent pharmacology of each peptide [2][13].
Does cjc-1295 ipamorelin work
Whether the cjc-1295 ipamorelin combination 'works' depends on the claim. Mechanistically, co-administering a GHRH analog with a secretagogue produces synergistic GH release in humans — that much is established at the class level [13][14]. But there is no controlled trial of the specific CJC-1295 + ipamorelin combination for fat loss, muscle gain, sleep, or anti-aging — the popular use cases [2]. So the GH-raising step is real and measurable; the downstream body-composition or wellness outcomes people seek from it remain unproven in any combination trial [2].
Ipamorelin vs sermorelin
Ipamorelin and sermorelin act on different receptors. Ipamorelin is a GHRP — a ghrelin-receptor (GHS-R1a) agonist that fires a GH pulse selectively [3]. Sermorelin is a GHRH analog (the first 29 amino acids of growth-hormone-releasing hormone) that acts on the GHRH receptor [3]. They are mechanistic complements rather than substitutes, which is exactly why a GHRP and a GHRH analog get stacked [3]. Ipamorelin's distinguishing trait is its cortisol/prolactin selectivity [3]; the head-to-head comparison is one of receptor class and selectivity, not of a single shared endpoint, since no trial pits them directly against each other.
Ipamorelin vs tesamorelin
Tesamorelin, like sermorelin, is a GHRH analog acting on the GHRH receptor, whereas ipamorelin is a ghrelin-receptor (GHS-R1a) secretagogue [3]. The two engage the somatotropic axis from different sides — GHRH-receptor drive versus GHS-R1a pulse — which is the same complementarity that underlies GHRH-analog-plus-GHRP stacking [3]. Their pharmacokinetics differ in kind as well: ipamorelin's defining human parameter is its ~2-hour terminal half-life with a single ~40-minute GH pulse [1]. As with sermorelin, no controlled study compares ipamorelin and tesamorelin directly on a shared outcome.